In the race to outsmart “untreatable” antibiotic-resistant gonorrhea, one of the three new treatments on the track is about to enter Phase 3 clinical trials. Hopefully, it’ll be widely accessible sooner rather than later, for the 78 million people who are diagnosed with gonorrhea each year.

Drug-resistant gonorrhea made headlines last week, earning the moniker “super gonorrhea” with its ability to outlast most treatments.

The bacteria Neisseria gonorrhea, a quickly-adapting pathogen, causes gonorrhea. It can often be transmitted orally, in which case the symptoms are easily mistaken for a… more


Go to Source

 

Comments are closed.